Cargando…

Risk of Central Serous Chorioretinopathy in Male Androgen Abusers

INTRODUCTION: Male gender is an important risk factor of central serous chorioretinopathy (CSC), and studies have explored the pathophysiological role of androgens in CSC with conflicting results. In this study, we shed light on this hot topic by exploring the risk of CSC in a large cohort of male a...

Descripción completa

Detalles Bibliográficos
Autores principales: Subhi, Yousif, Windfeld-Mathiasen, Josefine, Horwitz, Anna, Horwitz, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011293/
https://www.ncbi.nlm.nih.gov/pubmed/36692812
http://dx.doi.org/10.1007/s40123-023-00658-4
_version_ 1784906358572711936
author Subhi, Yousif
Windfeld-Mathiasen, Josefine
Horwitz, Anna
Horwitz, Henrik
author_facet Subhi, Yousif
Windfeld-Mathiasen, Josefine
Horwitz, Anna
Horwitz, Henrik
author_sort Subhi, Yousif
collection PubMed
description INTRODUCTION: Male gender is an important risk factor of central serous chorioretinopathy (CSC), and studies have explored the pathophysiological role of androgens in CSC with conflicting results. In this study, we shed light on this hot topic by exploring the risk of CSC in a large cohort of male androgen abusers. METHODS: This study included male androgen abusers identified through a nationwide anti-doping test program across Danish fitness centers from January 3 2006 to March 1 2018. For each case, we randomly sampled ten male controls using Danish nationwide registries. These controls were matched in age and date. Cases and controls were followed until May 16 2018. Data on diagnoses were extracted using the Danish National Registry of Patients using ICD-10 codes to identify cases with CSC. RESULTS: We included 1189 cases and 11,890 controls. Mean age at the time of doping sentence was 27.4 ± 6.9 years, and mean length of follow-up was 15.8 ± 3.6 years. We identified no cases of CSC in androgen abusers, and five cases of CSC in the control cohort. The difference between groups was not statistically significant (P = 1.0). CONCLUSIONS: Male androgen abusers were not at increased risk of CSC. Considering the lack of any signal in this large study, we speculate that if male androgen plays any direct role in the pathophysiology of CSC, its role may be subtle at best.
format Online
Article
Text
id pubmed-10011293
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-100112932023-03-15 Risk of Central Serous Chorioretinopathy in Male Androgen Abusers Subhi, Yousif Windfeld-Mathiasen, Josefine Horwitz, Anna Horwitz, Henrik Ophthalmol Ther Original Research INTRODUCTION: Male gender is an important risk factor of central serous chorioretinopathy (CSC), and studies have explored the pathophysiological role of androgens in CSC with conflicting results. In this study, we shed light on this hot topic by exploring the risk of CSC in a large cohort of male androgen abusers. METHODS: This study included male androgen abusers identified through a nationwide anti-doping test program across Danish fitness centers from January 3 2006 to March 1 2018. For each case, we randomly sampled ten male controls using Danish nationwide registries. These controls were matched in age and date. Cases and controls were followed until May 16 2018. Data on diagnoses were extracted using the Danish National Registry of Patients using ICD-10 codes to identify cases with CSC. RESULTS: We included 1189 cases and 11,890 controls. Mean age at the time of doping sentence was 27.4 ± 6.9 years, and mean length of follow-up was 15.8 ± 3.6 years. We identified no cases of CSC in androgen abusers, and five cases of CSC in the control cohort. The difference between groups was not statistically significant (P = 1.0). CONCLUSIONS: Male androgen abusers were not at increased risk of CSC. Considering the lack of any signal in this large study, we speculate that if male androgen plays any direct role in the pathophysiology of CSC, its role may be subtle at best. Springer Healthcare 2023-01-24 2023-04 /pmc/articles/PMC10011293/ /pubmed/36692812 http://dx.doi.org/10.1007/s40123-023-00658-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Subhi, Yousif
Windfeld-Mathiasen, Josefine
Horwitz, Anna
Horwitz, Henrik
Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
title Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
title_full Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
title_fullStr Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
title_full_unstemmed Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
title_short Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
title_sort risk of central serous chorioretinopathy in male androgen abusers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011293/
https://www.ncbi.nlm.nih.gov/pubmed/36692812
http://dx.doi.org/10.1007/s40123-023-00658-4
work_keys_str_mv AT subhiyousif riskofcentralserouschorioretinopathyinmaleandrogenabusers
AT windfeldmathiasenjosefine riskofcentralserouschorioretinopathyinmaleandrogenabusers
AT horwitzanna riskofcentralserouschorioretinopathyinmaleandrogenabusers
AT horwitzhenrik riskofcentralserouschorioretinopathyinmaleandrogenabusers